Anifrolumab clinical trials
Also written MEDI-546 and Saphnelo.
How each study uses anifrolumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anifrolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Jul 2021 · SAPHNELO · BLA 761123 (FDA, Drugs@FDA)
- European Union
- 14 Feb 2022 · Saphnelo · EMEA/H/C/004975 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 8
AstraZeneca (22) · MedImmune LLC (3) · University of North Carolina, Chapel Hill (1) · University of Cambridge (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · National and Kapodistrian University of Athens (1) · University Hospital, Bordeaux (1) · Oklahoma Medical Research Foundation (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 3 in phase 3
Studies that test anifrolumab, phase 3 first.
- Nov 2026A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 3 · AstraZeneca
- Jan 2027Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Phase 3 · AstraZeneca
- Feb 2027Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisPhase 3 · AstraZeneca
- Aug 2027The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDPhase 2 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Aug 2027Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersPhase 4 · AstraZeneca
- Sep 2027Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudyNot applicable · University of Cambridge
Studies
Open first, then newest update. How each study uses anifrolumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusRecruitingPhase 3AstraZenecaNCT07430306Written as Anifrolumab
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentRecruitingPhase 3AstraZenecaNCT07691970Written as Anifrolumab
- Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudyRecruitingNot applicableUniversity of CambridgeNCT07913919Written as Anifrolumab
- A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusRecruitingPhase 2AstraZenecaNCT07630714Written as Anifrolumab + APFS
- A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusRecruitingPhase 3AstraZenecaNCT07751848Written as Anifrolumab
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruitingPhase 3AstraZenecaNCT05835310Written as Anifrolumab
- A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)RecruitingPhase 3AstraZenecaNCT06455449Written as Anifrolumab (blinded)
- The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingPhase 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT05440422Written as anifrolumab
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruitingPhase 4AstraZenecaNCT06594068Written as Anifrolumab
- Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)Not yet recruitingPhase 1AstraZenecaNCT07688980Written as Anifrolumab: SC formulation via AI
- Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)RecruitingPhase 2National and Kapodistrian University of AthensNCT07584083Written as Anifrolumab
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active, not recruitingPhase 3AstraZenecaNCT05925803Written as Anifrolumab (blinded)
- A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusActive, not recruitingPhase 3AstraZenecaNCT06015737Written as Anifrolumab
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive, not recruitingPhase 3AstraZenecaNCT05138133Written as Anifrolumab
- Anifrolumab for Hidradenitis SuppurativaCompletedPhase 2University of North Carolina, Chapel HillNCT06374212Written as Anifrolumab
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusActive, not recruitingPhase 3AstraZenecaNCT04877691Written as Medi-546
- Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)CompletedPhase 3AstraZenecaNCT04931563Written as Anifrolumab
- Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult ParticipantsCompletedPhase 1AstraZenecaNCT06662123Written as Anifrolumab
- Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoStatus unknownPhase 2University Hospital, BordeauxNCT05917561Written as Anifrolumab Infusion Product
- Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLEStatus unknownEarly Phase 1Oklahoma Medical Research FoundationNCT04726553Written as Anifrolumab
See all 33 studies that test anifrolumab →
Given beside what is tested · 1 — anifrolumab is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudyNov 3, 2026NCT07913919
Codes
What other systems call anifrolumab · ClinicalTrials.gg INT006312
- MeSH (NLM) C582345anifrolumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 38RL9AE51QANIFROLUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2565265One source FDA
- Wikidata Q15708296AnifrolumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166658AnifrolumabOne source FDA
- DrugBank DB78910One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582345 | anifrolumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 38RL9AE51Q | ANIFROLUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2565265 | — | One source FDA |
| Wikidata | Q15708296 | Anifrolumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166658 | Anifrolumab | One source FDA |
| DrugBank | DB78910 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.